SCHEMBL16495808

SCHEMBL16495808

COc1cccc(-c2ccc(C(=O)NCC(C)(C)CN(C)C)cn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.51
TRPV1 Q8NER1 1/20 0.48
ROCK2 O75116 2/20 0.46
PRKG1 Q13976 2/20 0.46
PRKACA P17612 2/20 0.46
PRKACG P22612 1/20 0.46
PRKACB P22694 1/20 0.46
AKT1 P31749 1/20 0.46
LMNA P02545 1/20 0.43
HSP90AA1 P07900 1/20 0.43
FYN P06241 3/20 0.43
EGLN1 Q9GZT9 1/20 0.43
GRK5 P34947 1/20 0.42
PRKX P51817 1/20 0.42
PRKCQ Q04759 1/20 0.42
ROCK1 Q13464 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HSD17B2 P37059 1/20 0.41
RAD52 P43351 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495892 0.87 HPGDS (0.45) HPGDSPRKACGLMNAEGLN1KDM4E
SCHEMBL16495688 0.86 HPGDS (0.53) HPGDSPRKACGEGLN1
SCHEMBL16496335 0.85 HPGDS (0.55) HPGDSTRPV1ROCK2PRKG1PRKACA
SCHEMBL16495554 0.85 HPGDS (0.58) HPGDSTRPV1
SCHEMBL16495632 0.83 RAD52 (0.56) HPGDSTRPV1FYNEGLN1GRK5
SCHEMBL16495770 0.82 MAPK1 (0.60) HPGDSTRPV1ROCK2PRKG1PRKACA
SCHEMBL16495848 0.81 HPGDS (0.52) HPGDSTRPV1ROCK2PRKG1PRKACA
SCHEMBL16495729 0.79 ROCK2 (0.59) HPGDSTRPV1ROCK2PRKG1PRKACA
SCHEMBL16495474 0.79 MCHR1 (0.52) HPGDSPRKACG
SCHEMBL16496128 0.78 ALDH1A1 (0.55) HPGDSKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 HPGDS 1073/4885TRPV1 116/4885ROCK2 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.